Serbian Prime Minister Visits SK Bioscience... Signs Agreement for Domestic Vaccine Production Cooperation

SK Bioscience announced on the 8th that Serbian Prime Minister Ana Brnabi? visited its headquarters in Pangyo, Gyeonggi Province, and signed a Memorandum of Understanding (MOU) to establish a cooperative relationship between the two countries in vaccine development and production.

Serbian Prime Minister Ana Brnabi? visited SK Bioscience and signed a Memorandum of Understanding (MOU) to establish a cooperative relationship in vaccine development and production between the two countries. Ahn Jae-yong, President of SK Bioscience; Choi Chang-won, Vice Chairman of SK Discovery; Ana Brnabi?, Prime Minister of Serbia; and Kiran Naidu, CEO of Frontier Biopharma. (From left)
Photo by SK Bioscience

The MOU signing ceremony was attended by Nemanja Grbi?, Serbian Ambassador to Korea, Kiren Naidu, CEO of Frontier Biopharma, and other Serbian government and corporate officials. Lee Jae-woong, Ambassador of the Republic of Korea to Serbia, Choi Chang-won, Vice Chairman of SK Discovery, and Ahn Jae-yong, President of SK Bioscience, also participated.

Based on the MOU, the Serbian government, SK Bioscience, and Frontier Biopharma agreed to sign detailed contracts within the year and collaborate on establishing vaccine production facilities and commercialization in Serbia. SK Bioscience will prepare to carry out projects in Serbia utilizing its own vaccine research and development (R&D) and production capabilities, including ▲building and supporting a global-level production system ▲technology transfer and product commercialization ▲human resource development ▲R&D support ▲and transferring pandemic preparedness know-how.

The Serbian government will provide administrative support related to the project and cooperate to ensure that the completed products can be promptly supplied within Serbia. Frontier Biopharma will be responsible for the overall operation of the project.

Serbia imports most of its medical devices and pharmaceuticals from Europe, the United States, China, and other countries, resulting in high demand for vaccine localization. According to the "Current Status of Major Cooperation Areas between Korea and Serbia" published by the Korea Trade-Investment Promotion Agency (KOTRA), Serbia is actively promoting international collaboration by revitalizing investment in the bioindustry.

Through this cooperation with Serbia, SK Bioscience plans to lay the foundation for entering advanced markets such as the United States and Europe, while accelerating the entry of its self-developed vaccines into Europe.

Serbian Prime Minister Ana Brnabi? said, "This MOU is a representative example demonstrating Serbia's commitment to fostering various bioindustries such as biomedicine, biotechnology, bioinformatics, and biodiversity, as well as the investment value that global biopharmaceutical companies can secure in Serbia. We are very pleased to attract SK Bioscience, which will grow into a vaccine hub in Europe beyond Serbia."

Kiren Naidu, CEO of Frontier Biopharma, said, "We are pleased to cooperate with the Serbian government and SK Bioscience. Through close collaboration with SK Bioscience, which has world-class R&D and production technology enabling innovative next-generation vaccine development and production, we will build a production hub that provides the best products to the global market beyond Serbia."

Choi Chang-won, Vice Chairman of SK Discovery, stated, "Amid the increased global demand for vaccine self-sufficiency triggered by the pandemic, this collaboration demonstrates the competitiveness that SK Bioscience can contribute to the global health industry. We will achieve sustainable growth by contributing to the advancement of Serbia's vaccine industry and improving public health in more countries."

Meanwhile, Prime Minister Ana Brnabi?, who officially visited the Republic of Korea for the first time in 13 years since 2010, visited SK Bioscience as the only pharmaceutical and bio company during her stay in Korea.

This content was produced with the assistance of AI translation services.